177545-89-0

Basic information

• Product Name: TRANS-4-(BOC-AMINO)CYCLOHEXYL METHANESULFONATE
• Synonyms: TRANS-4-(BOC-AMINO)CYCLOHEXYL METHANESULFONATE;trans-4-(BOC-aMino)cyclohexyl Mesylate
• CAS NO: 177545-89-0
• Molecular Formula: C₁₂H₂₃NO₅S
• Molecular Weight: 293.38
• Mol File: 177545-89-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TRANS-4-(BOC-AMINO)CYCLOHEXYL METHANESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: TRANS-4-(BOC-AMINO)CYCLOHEXYL METHANESULFONATE(177545-89-0)
• EPA Substance Registry System: TRANS-4-(BOC-AMINO)CYCLOHEXYL METHANESULFONATE(177545-89-0)

Safety Data

• Hazardous Substances Data: 177545-89-0(Hazardous Substances Data)

Upstream product

• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 124-63-0 methanesulfonyl chloride 
• 111300-06-2 trans-tert-butyl 4-hydroxycyclohexylcarbamate 

Downstream Products

• 1272319-79-5 trans-4-aminocyclohexylmethanesulfonate trifluoroacetic acid salt 
• 1622401-46-0 benzyl(2-(7-azabicyclo[2.2.1]heptan-7-yl)-2-oxoethyl)carbamate 
• 91230-16-9 3-(N-tert-butoxycarbonylamino)cyclohexene 

Relevant articles and documents

ALKYNYL QUINAZOLINE COMPOUNDS

The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS

The invention relates to a compound represented by Formula (I): or a pharmaceutically acceptable salt thereof, compositions comprising the same and methods of preparing and using the same. The variables are described herein.

DNA-PK INHIBITORS

The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various diseases, conditions, or disorders.

POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.

SUBSTITUTED BENZAMIDES AND THEIR USES

Provided herein are Substituted Benzamides, compositions, and method of their manufacture and use.

1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS

The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.

TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS

The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R1, R2, ring A, and G are defined herein.

Inhibition of serine and proline racemases by substrate-product analogues

d-Amino acids can play important roles as specific biosynthetic building blocks required by organisms or act as regulatory molecules. Consequently, amino acid racemases that catalyze the formation of d-amino acids are potential therapeutic targets. Serine

CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM

In alternative embodiments, the invention provides nucleophilic hydroxyimino- acetamido alkylamine antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). The hydroxyimino-acetamido alkylamines of the invention are designed to fit within AChE active center gorge dimensions, bind with reasonable affinity, and react with the conjugated phosphate atom in the gorge. The hydroxyimino- acetamido alkylamines of the invention are also designed to possess ionization states that govern affinity and reactivity for the two linked hAChE re-activation steps. In alternative embodiments, the invention provides pumps, devices, subcutaneous infusion devices, continuous subcutaneous infusion devices, infusion pens, needles, reservoirs, ampoules, a vial, a syringe, a cartridge, a disposable pen or jet injector, a prefilled pen or a syringe or a cartridge, a cartridge or a disposable pen or jet injector, a two chambered or multi- chambered pump, a syringe, a cartridge or a pen or a jet injector, comprising a compound of the invention.